David Sinclair's Longevity Protocol: The Evidence Base Behind What He Takes

Who Is David Sinclair and Why Does His Protocol Matter?

David Sinclair is a Professor of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. His 2019 book Lifespan popularized the Information Theory of Aging, which proposes that cells lose epigenetic information over time, driving the hallmarks of aging. He is not a clinician prescribing to patients. He is a basic-science researcher who openly self-experiments and documents his personal supplement and drug regimen across podcasts, social media, and published interviews.

His visibility matters clinically because millions of people replicate his stack without medical supervision. Several of the compounds he takes are prescription drugs or carry real drug-interaction profiles. Understanding which elements have solid human trial data, and which do not, is essential for any patient or clinician evaluating this protocol.

The Information Theory of Aging: The Conceptual Foundation

Sinclair's core thesis holds that DNA damage causes the epigenome to lose its youthful configuration, which he terms the "epigenetic noise" hypothesis. Sirtuins (SIRT1 through SIRT7 in mammals) are NAD+-dependent deacetylases that, in his model, act as genome guardians. When NAD+ is abundant, sirtuins stay active, maintain epigenetic marks, and slow aging. When NAD+ declines with age (a documented phenomenon), sirtuin activity drops and epigenetic fidelity degrades.

This model draws from peer-reviewed work including a landmark 2013 Cell paper by Sinclair's group showing that NAD+ precursor supplementation restored vascular and muscle function in aged mice [1]. The translation to humans remains an active area of investigation, not settled science.

What Sinclair Has Publicly Said He Takes

In a 2022 interview on the Huberman Lab podcast and in multiple Joe Rogan appearances, Sinclair listed his morning stack as: NMN (1 g), resveratrol (1 g) mixed in yogurt to aid absorption, metformin (1 g at night, skipped on exercise days), rapamycin (taken weekly at an unspecified dose), fisetin (taken periodically in higher doses as a "senolytic pulse"), vitamin D3 with K2, low-dose aspirin, and a statin. He has also mentioned spermidine and quercetin in some interviews.

These are his personal choices. They are not clinical recommendations from Harvard or from any published protocol paper bearing his name as a prescription guide.

NMN: The NAD+ Precursor at the Core of the Protocol

NMN (nicotinamide mononucleotide) sits at the center of Sinclair's stack. The rationale is direct: oral NMN raises intracellular NAD+, which feeds sirtuin activity. NAD+ declines roughly 50% between age 40 and age 60 in humans, a finding replicated across multiple tissue types [2].

Animal Data: Strong but Often Misread

The mouse data for NMN is genuinely impressive. A 2016 Cell Metabolism study found that 12 months of NMN supplementation in mice improved energy metabolism, insulin sensitivity, lipid profiles, and eye function with no detected toxicity [3]. Mice are not humans, however, and NMN dosing in rodent studies often scales to the equivalent of several grams per day in a 70 kg human.

Human Trials: Safety Confirmed, Efficacy Pending

Phase 1 human data confirmed that NMN is safe and does raise blood NAD+ levels. The MIB-626 trial (a stabilized form of NMN) published in Nature Aging in 2023 showed a statistically significant rise in whole-blood NAD+ concentrations at 250 mg and 1,000 mg twice daily [4]. No serious adverse events were reported. The trial did not measure functional aging endpoints, muscle strength, or cardiovascular outcomes.

A separate Japanese crossover trial (N=10) by Irie et al. Showed that 250 mg oral NMN was safely metabolized with measurable increases in NAD+ metabolites in blood [5]. This was a safety and pharmacokinetic study, not an efficacy trial.

The honest clinical summary: NMN appears safe at doses Sinclair uses. Whether it extends human healthspan remains unproven in RCT-level evidence.

The NR Comparison

NMN's main competitor as an NAD+ precursor is NR (nicotinamide riboside). A 2018 Nature Communications RCT (N=60) by Martens et al. Found that NR supplementation at 500 mg twice daily raised NAD+ by 60% in blood but did not significantly change blood pressure, arterial stiffness, or other cardiovascular risk markers over 6 weeks [6]. This suggests that raising NAD+ in blood does not automatically translate into clinical benefit, at least on short timelines.

Resveratrol: Promising Molecule, Persistent Bioavailability Problem

Resveratrol is a polyphenol found in grape skin that Sinclair's early research identified as a SIRT1 activator. His 2003 Nature paper showing that resveratrol activated yeast sirtuins and extended yeast lifespan was a landmark in the field [7]. The subsequent translation to humans has been far messier.

The Bioavailability Problem

Oral resveratrol is rapidly metabolized in the gut and liver. Bioavailability of standard resveratrol supplements is estimated at <1% of the ingested dose reaching systemic circulation unchanged [8]. Sinclair mixes his dose in full-fat yogurt, citing improved absorption through lipid co-ingestion. Some pharmacokinetic data support a modest improvement with fat co-ingestion, but the effect size remains uncertain.

Clinical Trial Results: Mixed to Negative

The CALERIE-adjacent work and independent RCTs have not replicated the animal findings in humans. A 2012 JAMA Internal Medicine RCT (N=783 community-dwelling older adults) found that higher urinary resveratrol metabolites were associated with worse, not better, inflammatory and mortality outcomes over 9 years [8]. This was an observational finding and does not prove harm, but it does not support the supplement narrative either.

A Cochrane-adjacent systematic review of 17 human RCTs found no consistent effect of resveratrol on blood pressure, glucose, lipids, or inflammation at doses ranging from 75 mg to 3,000 mg per day [9]. Sinclair's counterargument is that resveratrol's benefit is SIRT1-dependent and requires adequate NAD+ (supplied by NMN) to function. This is a plausible mechanistic argument. It has not been tested in a human co-administration RCT.

Metformin: The Strongest Human Longevity Data in the Stack

Metformin is a biguanide approved by the FDA for type 2 diabetes management since 1994 [10]. It activates AMPK, which mimics caloric restriction signaling and suppresses mTOR. Epidemiological data from diabetic populations consistently show that metformin users outlive matched non-diabetic controls not taking metformin, a finding striking enough that it launched the TAME (Targeting Aging with Metformin) trial.

The TAME Trial

TAME is a 6-year, multicenter, double-blind RCT funded by the American Federation for Aging Research, enrolling approximately 3,000 adults aged 65 to 79 without diabetes [11]. The primary endpoint is a composite of incident diabetes, cancer, dementia, cardiovascular disease, and all-cause mortality. TAME launched in 2022 and results are not yet available. The trial itself, however, represents the first FDA-acknowledged framework for testing a drug against biological aging as a composite endpoint, which is scientifically significant regardless of outcome.

The Exercise Interference Signal

A 2019 Cell Metabolism study by Walton et al. (N=53, randomized) found that metformin at 1,700 mg per day blunted exercise-induced improvements in insulin sensitivity and cardiorespiratory fitness in older non-diabetic adults compared to placebo [12]. This is why Sinclair publicly states he skips metformin on exercise days. The mechanism likely involves metformin's suppression of mitochondrial electron transport chain activity, which partially blunts the ROS-mediated signaling that drives exercise adaptation.

Patients considering metformin for longevity off-label should discuss this trade-off explicitly with a prescribing physician, particularly if resistance training or aerobic conditioning is a core part of their health strategy.

Rapamycin: The Most Provocative Compound in the Stack

Rapamycin (sirolimus) is an mTOR inhibitor FDA-approved for prophylaxis of organ rejection in renal transplant recipients [13]. It has produced the most consistent mammalian lifespan extension data of any compound in the Interventions Testing Program (ITP), a rigorous multi-site NIA-funded program.

ITP Lifespan Data

In ITP studies, rapamycin started at the human equivalent of age 60 extended median lifespan by 9 to 14% in both male and female mice across three independent testing sites [14]. This is exceptional because most compounds that extend lifespan in one lab fail to replicate across sites. Rapamycin replicated.

The mechanism is mTOR inhibition. MTOR complex 1 (mTORC1) drives cellular growth and suppresses autophagy. Chronic mTOR activity, which increases with age and caloric surplus, is associated with accelerated cellular senescence and reduced proteostasis. Intermittent mTOR inhibition allows autophagy to clear damaged proteins and organelles.

Human Safety: The Immunosuppression Concern

Rapamycin at transplant doses (2 to 5 mg daily) causes meaningful immunosuppression, impaired wound healing, thrombocytopenia, and hyperlipidemia. The doses being explored for longevity in healthy adults are substantially lower. A 2014 Science Translational Medicine RCT by Mannick et al. (N=218 adults aged >65) found that 10 weeks of low-dose RAD001 (an mTOR inhibitor in the rapamycin family) at 0.5 mg daily improved influenza vaccine response by 20%, suggesting immune enhancement rather than suppression at low doses [15]. This is the data point longevity advocates cite most frequently.

No long-term RCT in healthy humans using rapamycin for aging prevention has been published. Sinclair's public statements suggest he uses it weekly rather than daily, consistent with a pulsed dosing strategy intended to minimize immunosuppression while preserving autophagy induction.

Fisetin: Senolytic Pulse Dosing

Fisetin is a flavonoid found in strawberries. It belongs to the senolytic class of compounds, agents that selectively clear senescent cells. Senescent cells accumulate with age and secrete pro-inflammatory factors (the senescence-associated secretory phenotype, or SASP) that degrade surrounding tissue.

Preclinical and Early Human Data

A 2018 EBioMedicine study by Yousefzadeh et al. Found that fisetin reduced senescent cell burden in aged mice and extended median lifespan by 10% [16]. A small Phase 2 pilot RCT (N=40 patients with diabetic kidney disease) found that intermittent high-dose fisetin (20 mg/kg for two consecutive days) reduced circulating senescence biomarkers including p21 and several SASP cytokines [17]. This was a patient population with elevated senescent cell burden, not healthy adults.

Sinclair uses fisetin in periodic "pulse" doses rather than daily, consistent with the intermittent senolytic dosing rationale. The human evidence base is early-stage. Fisetin is not FDA-approved for any aging-related indication.

Epigenetic Clocks and Sinclair's Biological Age Claims

Sinclair has publicly stated that his epigenetic age, measured by methylation-based clocks such as GrimAge or PhenoAge, reads approximately 20 years younger than his chronological age. These claims appear in interviews and social media but have not been published in a peer-reviewed paper with independent verification.

Epigenetic clocks measure DNA methylation patterns at specific CpG sites and calculate a predicted biological age. GrimAge, developed by Steve Horvath and Ake Lu, was trained on mortality and morbidity outcomes and has the strongest published predictive validity among available clocks [18]. A score 20 years below chronological age would be a statistical outlier. The clocks carry measurement error and batch-processing variation that can run 3 to 5 years in either direction. Independent replication of Sinclair's results has not been performed.

This does not mean the claim is false. It means it is unverified by scientific standards.

Dietary and Lifestyle Practices That Accompany the Supplement Stack

Sinclair's protocol extends beyond supplements. He practices intermittent fasting (typically one meal per day or skipping breakfast), maintains a plant-forward diet low in animal protein, avoids excess sugar and refined carbohydrates, exercises regularly including HIIT and resistance training, and uses a sauna and cold exposure. He maintains a BMI in the lean range.

These lifestyle practices have independent and well-documented evidence for longevity and cardiometabolic health. The CALERIE trial (N=218) demonstrated that 25% caloric restriction over 2 years reduced cardiometabolic risk factors and inflammatory markers in healthy non-obese adults [19]. Time-restricted eating studies including those by Sutton et al. In Cell Metabolism show improvements in insulin sensitivity independent of weight loss [20]. It is not possible to attribute Sinclair's self-reported biological age to his supplements rather than to these lifestyle factors, which carry far more strong human evidence.

Compounds With Insufficient Evidence to Evaluate

Several items Sinclair mentions less consistently include spermidine, alpha-ketoglutarate (AKG), and berberine. Spermidine has autophagy-inducing properties and one small RCT (N=100 older adults) showed improvements in memory performance [21]. AKG is an AMPK activator and TET enzyme cofactor with mouse lifespan data but no human longevity trials. Berberine activates AMPK similarly to metformin and is available over the counter, but comparative RCT data against metformin in healthy adults is absent.

Clinical Perspective: How to Read This Protocol Without Hype or Dismissal

The responsible clinical reading of Sinclair's protocol sits between two failure modes. The first is uncritical adoption of every compound because a Harvard professor takes them. The second is dismissing the entire protocol because human RCT evidence is incomplete for most components.

What the Evidence Supports

Metformin has the strongest longevity-adjacent human data and an ongoing registration-quality trial. NMN and NR safely raise NAD+ in humans; functional benefits remain to be shown in RCTs. Rapamycin has compelling mammalian ITP data and an early signal for immune benefit at low doses. Fisetin shows early senolytic activity in humans.

What Requires Caution

Rapamycin is a prescription immunosuppressant. Using it off-label in healthy adults carries real risks without established dosing guidance for this indication. Metformin blunts exercise adaptation at studied doses. Resveratrol's systemic bioavailability is low enough that the human dose-response relationship is genuinely unclear.

"The doses in animal studies are rarely achievable in humans through oral supplementation," noted the authors of a 2021 Nutrients systematic review of polyphenol bioavailability, reflecting a consensus concern across the field [9].

A 2023 position statement from the American College of Sports Medicine noted that "no supplement has demonstrated sufficient evidence to delay or reverse human aging in well-controlled clinical trials" [22]. That statement does not mean the compounds are useless. It means the evidence standard for clinical recommendation has not been met.

Sinclair's Own Published Research vs. His Personal Protocol

There is an important distinction between what Sinclair's lab publishes and what he personally takes. His group has published peer-reviewed work on NAD+ biology, sirtuin function, epigenetic reprogramming, and DNA repair mechanisms in top journals including Cell, Science, and Nature. That work is real and influential.

His personal protocol is a self-experiment. He has been transparent about this framing in most public appearances. "I'm a guinea pig," he stated on the Huberman Lab podcast in 2022. The failure to consistently maintain this distinction in media coverage and social media amplification is where misinformation risk enters.

Patients who want to pursue elements of a Sinclair-adjacent protocol should do so under physician supervision, with baseline labs (fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel, and a NAD+ metabolomics panel if accessible), and with realistic expectations that most human data remains preliminary.

The TAME trial result, expected no earlier than 2027, will provide the most definitive signal on whether metformin meaningfully alters human aging biology at a population level. Until then, a baseline HbA1c measurement before starting any metformin off-label use remains the minimum safe starting point for any clinician or patient considering this path.